Cargando…

Virulence traits and novel drug delivery strategies for mucormycosis post-COVID-19: a comprehensive review

The outbreak of a fatal black fungus infection after the resurgence of the cadaverous COVID-19 has exhorted scientists worldwide to develop a nutshell by repurposing or designing new formulations to address the crisis. Patients expressing COVID-19 are more susceptible to Mucormycosis (MCR) and thus...

Descripción completa

Detalles Bibliográficos
Autores principales: Faiyazuddin, Md., Sophia, A., Ashique, Sumel, Gholap, Amol D., Gowri, S., Mohanto, Sourav, Karthikeyan, C., Nag, Sagnik, Hussain, Arif, Akhtar, Mohammad Shabib, Bakht, Md. Afroz, Ahmed, Mohammed Gulzar, Rustagi, Sarvesh, Rodriguez-Morales, Alfonso J., Salas-Matta, Luis Andres, Mohanty, Aroop, Bonilla-Aldana, D. Katterine, Sah, Ranjit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561264/
https://www.ncbi.nlm.nih.gov/pubmed/37818370
http://dx.doi.org/10.3389/fimmu.2023.1264502
_version_ 1785117884430680064
author Faiyazuddin, Md.
Sophia, A.
Ashique, Sumel
Gholap, Amol D.
Gowri, S.
Mohanto, Sourav
Karthikeyan, C.
Nag, Sagnik
Hussain, Arif
Akhtar, Mohammad Shabib
Bakht, Md. Afroz
Ahmed, Mohammed Gulzar
Rustagi, Sarvesh
Rodriguez-Morales, Alfonso J.
Salas-Matta, Luis Andres
Mohanty, Aroop
Bonilla-Aldana, D. Katterine
Sah, Ranjit
author_facet Faiyazuddin, Md.
Sophia, A.
Ashique, Sumel
Gholap, Amol D.
Gowri, S.
Mohanto, Sourav
Karthikeyan, C.
Nag, Sagnik
Hussain, Arif
Akhtar, Mohammad Shabib
Bakht, Md. Afroz
Ahmed, Mohammed Gulzar
Rustagi, Sarvesh
Rodriguez-Morales, Alfonso J.
Salas-Matta, Luis Andres
Mohanty, Aroop
Bonilla-Aldana, D. Katterine
Sah, Ranjit
author_sort Faiyazuddin, Md.
collection PubMed
description The outbreak of a fatal black fungus infection after the resurgence of the cadaverous COVID-19 has exhorted scientists worldwide to develop a nutshell by repurposing or designing new formulations to address the crisis. Patients expressing COVID-19 are more susceptible to Mucormycosis (MCR) and thus fall easy prey to decease accounting for this global threat. Their mortality rates range around 32-70% depending on the organs affected and grow even higher despite the treatment. The many contemporary recommendations strongly advise using liposomal amphotericin B and surgery as first-line therapy whenever practicable. MCR is a dangerous infection that requires an antifungal drug administration on appropriate prescription, typically one of the following: Amphotericin B, Posaconazole, or Isavuconazole since the fungi that cause MCR are resistant to other medications like fluconazole, voriconazole, and echinocandins. Amphotericin B and Posaconazole are administered through veins (intravenously), and isavuconazole by mouth (orally). From last several years so many compounds are developed against invasive fungal disease but only few of them are able to induce effective treatment against the micorals. Adjuvant medicines, more particularly, are difficult to assess without prospective randomized controlled investigations, which are challenging to conduct given the lower incidence and higher mortality from Mucormycosis. The present analysis provides insight into pathogenesis, epidemiology, clinical manifestations, underlying fungal virulence, and growth mechanisms. In addition, current therapy for MCR in Post Covid-19 individuals includes conventional and novel nano-based advanced management systems for procuring against deadly fungal infection. The study urges involving nanomedicine to prevent fungal growth at the commencement of infection, delay the progression, and mitigate fatality risk.
format Online
Article
Text
id pubmed-10561264
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105612642023-10-10 Virulence traits and novel drug delivery strategies for mucormycosis post-COVID-19: a comprehensive review Faiyazuddin, Md. Sophia, A. Ashique, Sumel Gholap, Amol D. Gowri, S. Mohanto, Sourav Karthikeyan, C. Nag, Sagnik Hussain, Arif Akhtar, Mohammad Shabib Bakht, Md. Afroz Ahmed, Mohammed Gulzar Rustagi, Sarvesh Rodriguez-Morales, Alfonso J. Salas-Matta, Luis Andres Mohanty, Aroop Bonilla-Aldana, D. Katterine Sah, Ranjit Front Immunol Immunology The outbreak of a fatal black fungus infection after the resurgence of the cadaverous COVID-19 has exhorted scientists worldwide to develop a nutshell by repurposing or designing new formulations to address the crisis. Patients expressing COVID-19 are more susceptible to Mucormycosis (MCR) and thus fall easy prey to decease accounting for this global threat. Their mortality rates range around 32-70% depending on the organs affected and grow even higher despite the treatment. The many contemporary recommendations strongly advise using liposomal amphotericin B and surgery as first-line therapy whenever practicable. MCR is a dangerous infection that requires an antifungal drug administration on appropriate prescription, typically one of the following: Amphotericin B, Posaconazole, or Isavuconazole since the fungi that cause MCR are resistant to other medications like fluconazole, voriconazole, and echinocandins. Amphotericin B and Posaconazole are administered through veins (intravenously), and isavuconazole by mouth (orally). From last several years so many compounds are developed against invasive fungal disease but only few of them are able to induce effective treatment against the micorals. Adjuvant medicines, more particularly, are difficult to assess without prospective randomized controlled investigations, which are challenging to conduct given the lower incidence and higher mortality from Mucormycosis. The present analysis provides insight into pathogenesis, epidemiology, clinical manifestations, underlying fungal virulence, and growth mechanisms. In addition, current therapy for MCR in Post Covid-19 individuals includes conventional and novel nano-based advanced management systems for procuring against deadly fungal infection. The study urges involving nanomedicine to prevent fungal growth at the commencement of infection, delay the progression, and mitigate fatality risk. Frontiers Media S.A. 2023-09-25 /pmc/articles/PMC10561264/ /pubmed/37818370 http://dx.doi.org/10.3389/fimmu.2023.1264502 Text en Copyright © 2023 Faiyazuddin, Sophia, Ashique, Gholap, Gowri, Mohanto, Karthikeyan, Nag, Hussain, Akhtar, Bakht, Ahmed, Rustagi, Rodriguez-Morales, Salas-Matta, Mohanty, Bonilla-Aldana and Sah https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Faiyazuddin, Md.
Sophia, A.
Ashique, Sumel
Gholap, Amol D.
Gowri, S.
Mohanto, Sourav
Karthikeyan, C.
Nag, Sagnik
Hussain, Arif
Akhtar, Mohammad Shabib
Bakht, Md. Afroz
Ahmed, Mohammed Gulzar
Rustagi, Sarvesh
Rodriguez-Morales, Alfonso J.
Salas-Matta, Luis Andres
Mohanty, Aroop
Bonilla-Aldana, D. Katterine
Sah, Ranjit
Virulence traits and novel drug delivery strategies for mucormycosis post-COVID-19: a comprehensive review
title Virulence traits and novel drug delivery strategies for mucormycosis post-COVID-19: a comprehensive review
title_full Virulence traits and novel drug delivery strategies for mucormycosis post-COVID-19: a comprehensive review
title_fullStr Virulence traits and novel drug delivery strategies for mucormycosis post-COVID-19: a comprehensive review
title_full_unstemmed Virulence traits and novel drug delivery strategies for mucormycosis post-COVID-19: a comprehensive review
title_short Virulence traits and novel drug delivery strategies for mucormycosis post-COVID-19: a comprehensive review
title_sort virulence traits and novel drug delivery strategies for mucormycosis post-covid-19: a comprehensive review
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561264/
https://www.ncbi.nlm.nih.gov/pubmed/37818370
http://dx.doi.org/10.3389/fimmu.2023.1264502
work_keys_str_mv AT faiyazuddinmd virulencetraitsandnoveldrugdeliverystrategiesformucormycosispostcovid19acomprehensivereview
AT sophiaa virulencetraitsandnoveldrugdeliverystrategiesformucormycosispostcovid19acomprehensivereview
AT ashiquesumel virulencetraitsandnoveldrugdeliverystrategiesformucormycosispostcovid19acomprehensivereview
AT gholapamold virulencetraitsandnoveldrugdeliverystrategiesformucormycosispostcovid19acomprehensivereview
AT gowris virulencetraitsandnoveldrugdeliverystrategiesformucormycosispostcovid19acomprehensivereview
AT mohantosourav virulencetraitsandnoveldrugdeliverystrategiesformucormycosispostcovid19acomprehensivereview
AT karthikeyanc virulencetraitsandnoveldrugdeliverystrategiesformucormycosispostcovid19acomprehensivereview
AT nagsagnik virulencetraitsandnoveldrugdeliverystrategiesformucormycosispostcovid19acomprehensivereview
AT hussainarif virulencetraitsandnoveldrugdeliverystrategiesformucormycosispostcovid19acomprehensivereview
AT akhtarmohammadshabib virulencetraitsandnoveldrugdeliverystrategiesformucormycosispostcovid19acomprehensivereview
AT bakhtmdafroz virulencetraitsandnoveldrugdeliverystrategiesformucormycosispostcovid19acomprehensivereview
AT ahmedmohammedgulzar virulencetraitsandnoveldrugdeliverystrategiesformucormycosispostcovid19acomprehensivereview
AT rustagisarvesh virulencetraitsandnoveldrugdeliverystrategiesformucormycosispostcovid19acomprehensivereview
AT rodriguezmoralesalfonsoj virulencetraitsandnoveldrugdeliverystrategiesformucormycosispostcovid19acomprehensivereview
AT salasmattaluisandres virulencetraitsandnoveldrugdeliverystrategiesformucormycosispostcovid19acomprehensivereview
AT mohantyaroop virulencetraitsandnoveldrugdeliverystrategiesformucormycosispostcovid19acomprehensivereview
AT bonillaaldanadkatterine virulencetraitsandnoveldrugdeliverystrategiesformucormycosispostcovid19acomprehensivereview
AT sahranjit virulencetraitsandnoveldrugdeliverystrategiesformucormycosispostcovid19acomprehensivereview